era-net pathogenomics m. karrasch, fzj 23.05.2005
Post on 12-Jan-2016
219 Views
Preview:
TRANSCRIPT
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
www.pathogenomics-era.net
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
1. What is an ERA-NET?
2. Structure of the ERA-NET PathoGenoMics / Boards, Work programme and activities
3. Transnational Research Activities
4. The today‘s subject: Strategic Research Agenda
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
ERA-NET: new instrument within the FP 6 Objective: “Strengthening the European Research Area“ (ERA)
ERA-NET Schema
Objective:
development and implementation of joint research activities
enhance the cooperation and coordination of national research activities
- through networking of national/regional programmes including their mutual opening and the
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
ERA-NET Scheme
Eligible Partners:
Partners are programme owners/managers acting on behalf of national/regional public authorities :
such as ministries, funding agencies, research councils
ERA-NET does not include direct research funding, but
all measures for intergovernmental coordination of existing
or new funding programmes.
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
1. What is an ERA-NET?
2. Structure of the ERA-NET PathoGenoMics / Boards, Work programme and activities
3. Transnational Research Activities
4. The today‘s subject: Strategic Research Agenda
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Network Steering CommitteeNSC
Funding Organisations
Affiliated PartnersFunding Organisations
External Advisory BoardEAB
Scientists
Boards
Executing Board EBProgramme/Project Management
CoordinatorJoint SecretariatAdministration
EuropeanCommission
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
ERA-NET Schema
Activities:
1. Systematic exchange of information & “best practices”
2. Common strategies
3. Development of common activities
4. Implementation of transnational research activities
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
WP 7Development of a legal, contractual and financial Framework and application/ evaluation system
01/2006
WP 3development of a „European Research Agenda“
WP 1 + 2
information exchange about the national programmes
Commitment of the partners regarding joint call
WP 8first
Joint call
2005 2006
Agreement on „European Research Agenda“
9/2005
Agreement Framework and application/ evaluation system
Development of transnationalresearch consortia
WP 6Partne-ring Event
4/2005
WP 4 SMEs/industry working group, PIPs network (PathoGenoMics innovation partners)
WP 6 Working group on training issues
WP 9 Science and Society: IT-based communication platforms for the public, Printed information material, On-spot-presentations
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Work programmemilestones
deliverables
WP 7 development of the admin. framework + Application/ evaluation system
WP 6 working group „training issues“
WP 4 SMEs/industry working group
WP 9 Wissenschaft und Gesellschaft: Kommunikationsplattform
WP 6 development of transnationalresearch concortia
WP 3 development of a „strategic Research Agenda“
Austria, Finland,France, Germany,Slovenia, Spain
maybe: Portugal, Sweden
12/2005
WP 1 + 2
information exchange about the national programmes
Commitment of the partners regarding joint call
2005 2006
Agreement about SRA
9/2005
Agreement about admin. framework and appl./ eval. system
4/2005
2007
WP 81st
jointcall WP 8
Project execution
WP 82ndjointcall
Partne-ring Event
Call text and IPR guideline:1st draft 04/05
2nd and 3rd draft 05/05final version 08/05
2004
10/2004Start
Strategic Research Agenda:1st draft 06/05
final version 09/05
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Public accessible database, contains information about and allows searches for:
- Research groups in the Pathogenomics field- topics of current research projects- Studied microorganisms
Will probably be available in 4 weeks-> please supplement these information with e.g.
summaries of your own research topics, link to your web page…
WP 9 Science and Society: IT-based communication platforms for the public, Printed information material, On-spot-presentations
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
1. What is an ERA-NET?
2. Structure of the ERA-NET PathoGenoMics / Boards, Work programme and activities
3. Transnational Research Activities
4. The today‘s subject: Strategic Research Agenda
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Transnational Research Activities:
- „nationality principle“ (each country shall fund ist own research entities)
- countries participating in the first joint call:
maybe also participating:
- research groups from other countries may also participate, provided they have their own funding
Austria, Finland, Germany, Slovenia, Spain
France, Israel, Latvia, Portugal, Sweden
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Transnational Research Activities:
- who may submit proposals?Research groups, organised in transnational consortia, will submit a consorted proposal
- which topics will be funded?Topics covering Genome Research on pathogenic
Microorganisms (details will be given in the call for proposals, approx. Jan. 2006)
- will there be further regulations?yes, e.g. transnational research consortia, consorted proposalsvariable geometrie; details are still to be definedfurther regulations will be published in the call text
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
1. What is an ERA-NET?
2. Structure of the ERA-NET PathoGenoMics / Boards, Work programme and activities
3. Transnational Research Activities
4. The today‘s subject: Strategic Research Agenda for PathoGenoMics
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Agreement on SRA
Helsinki26.-27.09.05
Expert Meeting: indepth discussion about SRA, develop-ment of a first draft SRA by Rapporteurs
2005
Paris23.-25.05.05 06/2005
Publication of the SRA draft in FEMS letters (and other journals)
07/2005
Scientific feedback
Time schedule: Strategic Research Agenda (SRA)
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Workpackage 3: Strategic Research Agenda (SRA)
Why a Strategic Research Agenda for PathoGenoMics?
To define the most important topics for future PathoGenoMics researchTo outline the importance of this topic
-> basis for discussions with
- national funding authorities (e.g. development of new programmes)- European Commission- other stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Pathogenomics: A Proposed European Research Agenda
A: The microbes
B: Host-microbe interactions
C: Development and improvement of tools
D. Integration at a European Level
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
T 3.2 Indepth discussion with high-level experts, 23rd – 25th May 2005, Paris
Based on first ideas to structure a European Research Agendadeveloped on a 1st preparatory meeting (June 2003, Würzburg)
3.2(a) Civil Aspects of pathogenomics3.2(b) Impact of pathogenomics on biosecurity and safety research
Workpackage 3: Strategic Research Agenda (SRA)
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
T 3.3 Feedback from the scientific community
“Rapporteurs“ will summarise the indepths expert discussion and continue drafting the agenda (up to 20 pages)
Draft Research Agenda will be published in FEMS Letters in order to create a scientific „feedback loop“ (deadline approx. 2 months)
final version of the „European Pathogenomics Research Agenda“in September 2005
Workpackage 3: Strategic Research Agenda (SRA)
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Partner Country Participation in the first call to be published in January 2006
Participation in the second call to be published in January 2007
Austria (bm:bwk) Yes Yes
Finland Yes Yes
France maybe maybe
Germany Yes Yes
Hungary
Israel maybe maybe
Latvia maybe maybe
Portugal maybe maybe
Slovenia Yes Yes
Spain Yes Yes
Affiliated Partners
Austria (FWF) No No
Lithuania Yes Yes
Malta Yes Yes
Netherlands No No
Norway
Sweden maybe maybe
UK (BBSRC) No No
UK (WT)
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
Partner Country
External Advisory BoardName Institute/ Company
1 + 2, Germany
Prof. Dr. Matthias Frosch Institut für Hygiene und Mikrobiologie, University of Wuerzburg
Prof. Dr. Klaus-Peter Koller Aventis Deutschland GmbH, Frankfurt
3, Austria Prof. Dr. Heinz Redl LBI für exp. und klin. Traumatologie, Unfallkrankenh. L. Böhler, Wien
Prof. Dr. Michael Wagner Abt. Mikrobielle Ökologie, Institut für Ökologie, Universität Wien
4, Finland Prof. Timo Korhonen University of Helsinki
Prof. Mikael Skurnik University of Helsinki
5, France Prof. Dr. Michele Mock Institute Pasteur, Paris
Prof. Dr. Christophe d'Enfert Unité Biologie et Pathogenicite Fongiques, Institute Pasteur, Paris
Prof. Dr. Andrée Lazdunski IBSM / CNRS Marseille
6, Hungary Prof. Dr. Béla Nagy Vet. Med. Research Inst. of the Hung. Academy of Sciences, Budapest
Prof. Dr. Levente Emody University of Pécs, Faculty of Medicine
7, Israel Prof. Dr. Eliora Z. Ron Faculty of Life Sciences, Tel-Aviv University
8, Latvia Prof. Pauls Pumpens University of Latvia, Biological Faculty
Prof. Vaija Zilevica University of Latvia, Medical Faculty
9, Portugal
10, Slovenia
Prof. Dr. Peter Raspor Chair for Biotechnology, Biotechnical Faculty, University of Ljubljana
Asst.prof. Dr. Roman Jerala Laboratory of Biotechnology, National Institute of Chemistry, Ljubljana
11, Spain Prof. Dr. Francisco García-del Portillo
Centro Nacional de Biotechnología, Campus de Cantoblanco, Madrid
Prof. Dr. Carlos Martin University of Zaragoza
ERA-NET PathoGenoMics
M. Karrasch, FZJ23.05.2005
top related